Summary
Merck & Co., Inc. (MRK) reported its financial results for the second quarter and the first six months ended June 30, 2012. For the second quarter, total sales increased slightly to $12.31 billion, while net income attributable to Merck & Co., Inc. was $1.79 billion, a decrease from $2.02 billion in the prior year quarter. The six-month period saw sales rise to $24.04 billion, with net income attributable to Merck & Co., Inc. at $3.53 billion, an increase from $3.13 billion in the comparable period of 2011. The company experienced growth in key pharmaceutical products such as Januvia and Janumet, driven by strong international and U.S. performance. However, sales were impacted by the ongoing European economic challenges, pricing pressures, and the upcoming patent expiration of Singulair in the U.S. in August 2012, which is expected to significantly reduce future sales. Restructuring costs related to the integration of Schering-Plough continue to impact expenses, although the company is realizing annual savings from these initiatives. The company also provided an update on its R&D pipeline, highlighting progress in key areas and strategic collaborations.
Financial Highlights
50 data points| Revenue | $12.31B |
| Cost of Revenue | $4.11B |
| Gross Profit | $8.20B |
| R&D Expenses | $2.17B |
| SG&A Expenses | $3.25B |
| Interest Expense | $172.00M |
| Net Income | $1.79B |
| EPS (Basic) | $0.59 |
| EPS (Diluted) | $0.58 |
| Shares Outstanding (Basic) | 3.04B |
| Shares Outstanding (Diluted) | 3.07B |
Key Highlights
- 1Total sales for the second quarter of 2012 increased by 1% year-over-year to $12.31 billion, while sales for the first six months increased by 1% to $24.04 billion.
- 2Net income attributable to Merck & Co., Inc. decreased by 11.4% to $1.79 billion ($0.58 per diluted share) in Q2 2012, compared to $2.02 billion ($0.65 per diluted share) in Q2 2011. However, for the first six months, net income increased by 14.8% to $3.53 billion ($1.15 per diluted share) compared to $3.13 billion ($0.98 per diluted share) in the prior year period.
- 3Key pharmaceutical products like Januvia and Janumet showed strong growth, with Januvia sales up 36% and Janumet up 28% in the second quarter.
- 4The company incurred significant restructuring costs related to the Merger Restructuring Program, with total pretax restructuring costs of $291 million in Q2 2012 and $568 million in the first six months of 2012.
- 5Singulair, a major revenue driver, is facing upcoming patent expirations in the U.S. (August 2012) and Europe (February 2013), which is expected to lead to a significant sales decline.
- 6Merck is actively managing its R&D pipeline, with updates on key drug candidates like odanacatib, suvorexant, and vintafolide.
- 7The company's financial position remains strong, with $16.75 billion in cash and cash equivalents at the end of the second quarter of 2012.